KR102569226B1 - 운동실조 모세혈관확장증 및 Rad3-관련 (ATR) 단백질 키나제 억제제 - Google Patents
운동실조 모세혈관확장증 및 Rad3-관련 (ATR) 단백질 키나제 억제제 Download PDFInfo
- Publication number
- KR102569226B1 KR102569226B1 KR1020177012838A KR20177012838A KR102569226B1 KR 102569226 B1 KR102569226 B1 KR 102569226B1 KR 1020177012838 A KR1020177012838 A KR 1020177012838A KR 20177012838 A KR20177012838 A KR 20177012838A KR 102569226 B1 KR102569226 B1 KR 102569226B1
- Authority
- KR
- South Korea
- Prior art keywords
- atoms
- group
- formula
- alkyl
- compound
- Prior art date
Links
Images
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D498/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
- C07D498/08—Bridged systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/4985—Pyrazines or piperazines ortho- or peri-condensed with heterocyclic ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5375—1,4-Oxazines, e.g. morpholine
- A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D498/12—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains three hetero rings
- C07D498/18—Bridged systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D515/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen, oxygen, and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00
- C07D515/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen, oxygen, and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00 in which the condensed system contains two hetero rings
- C07D515/08—Bridged systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D515/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen, oxygen, and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00
- C07D515/12—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen, oxygen, and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00 in which the condensed system contains three hetero rings
- C07D515/18—Bridged systems
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Hematology (AREA)
- Oncology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Biomedical Technology (AREA)
- Pathology (AREA)
- Radiology & Medical Imaging (AREA)
- Plural Heterocyclic Compounds (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (5)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201462063176P | 2014-10-13 | 2014-10-13 | |
US62/063,176 | 2014-10-13 | ||
US201562104274P | 2015-01-16 | 2015-01-16 | |
US62/104,274 | 2015-01-16 | ||
PCT/US2015/055317 WO2016061097A1 (en) | 2014-10-13 | 2015-10-13 | Ataxia telengiectasia and rad3-related (atr) protein kinase inhibitors |
Publications (2)
Publication Number | Publication Date |
---|---|
KR20170082532A KR20170082532A (ko) | 2017-07-14 |
KR102569226B1 true KR102569226B1 (ko) | 2023-08-22 |
Family
ID=55654998
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
KR1020177012838A KR102569226B1 (ko) | 2014-10-13 | 2015-10-13 | 운동실조 모세혈관확장증 및 Rad3-관련 (ATR) 단백질 키나제 억제제 |
Country Status (12)
Families Citing this family (13)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CA2963973C (en) | 2014-10-13 | 2023-01-10 | Atrin Pharmaceuticals LLC | Macrocylic compounds as ataxia telengiectasia and rad3-related (atr) protein kinase inhibitors |
WO2017180723A1 (en) * | 2016-04-12 | 2017-10-19 | Atrin Pharmaceuticals LLC | Ataxia telengiectasia and rad3-related (atr) inhibitors and methods of their use |
EP3630116B1 (en) | 2017-05-26 | 2024-05-01 | The Board Of Regents Of The University Of Texas System | Tetrahydropyrido[4,3-d]pyrimidine inhibitors of atr kinase |
CN117466884A (zh) | 2017-07-13 | 2024-01-30 | 德州大学系统董事会 | 用作atr激酶抑制剂的杂环化合物或其盐、包含其的药物组合物及用途 |
CN111886224A (zh) | 2017-08-17 | 2020-11-03 | 德州大学系统董事会 | Atr激酶的杂环抑制剂 |
US11267809B2 (en) | 2017-09-14 | 2022-03-08 | The Board Of Trustees Of The Leland Stanford Junior University | BAF complex modulating compounds and methods of using the same |
US10894052B2 (en) | 2018-03-16 | 2021-01-19 | Board Of Regents, The University Of Texas System | Heterocyclic inhibitors of ATR kinase |
CN110357905B (zh) * | 2018-03-26 | 2021-10-01 | 武汉誉祥医药科技有限公司 | 作为蛋白激酶抑制剂的大环类衍生物及其制备方法和用途 |
EP3820460A1 (en) | 2018-07-12 | 2021-05-19 | The Board of Trustees of the Leland Stanford Junior University | Methods for reversing hiv latency using baf complex modulating compounds |
CN110950890B (zh) * | 2018-09-27 | 2022-07-01 | 北京赛林泰医药技术有限公司 | 取代的咪唑并[4,5-c]喹啉大环化合物作为多靶点激酶抑制剂 |
AU2021360636A1 (en) | 2020-10-16 | 2023-06-15 | Shanghai De Novo Pharmatech Co., Ltd. | Triheterocyclic derivative, and pharmaceutical composition and application thereof |
WO2023201320A1 (en) | 2022-04-14 | 2023-10-19 | Atrin Pharmaceuticals LLC | Atr inhibitors |
WO2023242302A1 (en) | 2022-06-15 | 2023-12-21 | Astrazeneca Ab | Combination therapy for treating cancer |
Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2010071837A1 (en) | 2008-12-19 | 2010-06-24 | Vertex Pharmaceuticals Incorporated | Pyrazine derivatives useful as inhibitors of atr kinase |
WO2011143425A2 (en) | 2010-05-12 | 2011-11-17 | Vertex Pharmaceuticals Incorporated | Compounds useful as inhibitors of atr kinase |
WO2015050989A2 (en) | 2013-10-01 | 2015-04-09 | Cs Therapeutics Inc. | Macrocyclic compounds for the treatment of proliferative diseases |
Family Cites Families (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
NZ541861A (en) | 2003-02-26 | 2009-05-31 | Sugen Inc | Aminoheteroaryl compounds as protein kinase inhibitors |
US7163939B2 (en) * | 2003-11-05 | 2007-01-16 | Abbott Laboratories | Macrocyclic kinase inhibitors |
EP2686323A1 (en) * | 2011-03-16 | 2014-01-22 | Cephalon, Inc. | Macrocyclic compounds as alk, fak and jak2 inhibitors |
HUE034118T2 (en) * | 2012-03-06 | 2018-01-29 | Pfizer | Macrocyclic derivatives for the treatment of proliferative diseases |
DK2836485T3 (en) * | 2012-03-17 | 2018-04-23 | Polyphor Ag | CONFORMITY LIMITED, FULLY SYNTHETIC MACROCYCLIC COMPOUNDS |
CA2963973C (en) | 2014-10-13 | 2023-01-10 | Atrin Pharmaceuticals LLC | Macrocylic compounds as ataxia telengiectasia and rad3-related (atr) protein kinase inhibitors |
-
2015
- 2015-10-13 CA CA2963973A patent/CA2963973C/en active Active
- 2015-10-13 EP EP15850553.7A patent/EP3207031B1/en active Active
- 2015-10-13 AU AU2015333738A patent/AU2015333738B2/en active Active
- 2015-10-13 MX MX2017004515A patent/MX2017004515A/es unknown
- 2015-10-13 KR KR1020177012838A patent/KR102569226B1/ko active IP Right Grant
- 2015-10-13 WO PCT/US2015/055317 patent/WO2016061097A1/en active Application Filing
- 2015-10-13 ES ES15850553T patent/ES2879441T3/es active Active
- 2015-10-13 CN CN201580067182.7A patent/CN107108527B/zh active Active
- 2015-10-13 US US14/881,680 patent/US9663535B2/en active Active
- 2015-10-13 JP JP2017538930A patent/JP6678679B2/ja active Active
- 2015-10-13 BR BR112017007708A patent/BR112017007708B8/pt active Search and Examination
-
2017
- 2017-04-05 IL IL251595A patent/IL251595B/en unknown
- 2017-04-27 US US15/498,631 patent/US9981989B2/en active Active
-
2018
- 2018-04-12 US US15/951,302 patent/US10196405B2/en active Active
Patent Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2010071837A1 (en) | 2008-12-19 | 2010-06-24 | Vertex Pharmaceuticals Incorporated | Pyrazine derivatives useful as inhibitors of atr kinase |
WO2011143425A2 (en) | 2010-05-12 | 2011-11-17 | Vertex Pharmaceuticals Incorporated | Compounds useful as inhibitors of atr kinase |
WO2015050989A2 (en) | 2013-10-01 | 2015-04-09 | Cs Therapeutics Inc. | Macrocyclic compounds for the treatment of proliferative diseases |
Also Published As
Publication number | Publication date |
---|---|
US10196405B2 (en) | 2019-02-05 |
US20180230168A1 (en) | 2018-08-16 |
MX2017004515A (es) | 2017-10-31 |
AU2015333738A1 (en) | 2017-05-04 |
US20160102104A1 (en) | 2016-04-14 |
KR20170082532A (ko) | 2017-07-14 |
ES2879441T3 (es) | 2021-11-22 |
CA2963973C (en) | 2023-01-10 |
US9663535B2 (en) | 2017-05-30 |
CN107108527B (zh) | 2022-08-02 |
EP3207031B1 (en) | 2021-04-14 |
JP6678679B2 (ja) | 2020-04-08 |
WO2016061097A1 (en) | 2016-04-21 |
BR112017007708A2 (pt) | 2017-12-19 |
JP2017531041A (ja) | 2017-10-19 |
IL251595A0 (en) | 2017-06-29 |
IL251595B (en) | 2022-04-01 |
AU2015333738B2 (en) | 2020-03-26 |
BR112017007708B8 (pt) | 2023-10-24 |
EP3207031A4 (en) | 2018-02-14 |
BR112017007708B1 (pt) | 2023-07-25 |
US9981989B2 (en) | 2018-05-29 |
BR112017007708A8 (US07794700-20100914-C00125.png) | 2017-12-19 |
CN107108527A (zh) | 2017-08-29 |
CA2963973A1 (en) | 2016-04-21 |
US20170226130A1 (en) | 2017-08-10 |
EP3207031A1 (en) | 2017-08-23 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
KR102569226B1 (ko) | 운동실조 모세혈관확장증 및 Rad3-관련 (ATR) 단백질 키나제 억제제 | |
TWI827646B (zh) | Ptpn11抑制劑 | |
CA2969090C (en) | Triazolopyrimidine compounds and uses thereof | |
CN107922431B (zh) | Hpk1抑制剂及其使用方法 | |
JP5389785B2 (ja) | キナーゼ阻害剤として有用なチアゾールおよびピラゾール | |
WO2018031680A1 (en) | Novel compounds, uses and methods for their preparation | |
KR20130129244A (ko) | 치환된 6,6-융합된 질소 헤테로환형 화합물 및 이의 용도 | |
EP3472161B1 (en) | Triazolopyridine compounds and uses thereof | |
JP2016512816A (ja) | Atrキナーゼの阻害剤として有用な化合物 | |
JP2013526540A (ja) | Atrキナーゼ阻害剤として有用な化合物 | |
JP2016512815A (ja) | Atrキナーゼの阻害剤として有用な縮合ピラゾロピリミジン誘導体 | |
CA2785923A1 (en) | Therapeutic compounds and related methods of use | |
JP2010514676A (ja) | タンパク質キナーゼ阻害剤として有用な5−シアノ−4−(ピロロ[2,3b]ピリジン−3−イル)−ピリミジン誘導体 | |
JP2010528021A (ja) | キナーゼのインヒビターとして有用なチアゾールおよびピラゾール | |
JP2010524962A (ja) | オーロラキナーゼ阻害剤のための創薬法 | |
CA3163389A1 (en) | Biphenyl derivative inhibitor, preparation method therefor and use thereof | |
JP2016540773A (ja) | Atrキナーゼの阻害剤として有用な化合物 | |
CN108558833B (zh) | 吡唑醇类化合物、其药物组合物及其在药物中的应用 | |
KR101777475B1 (ko) | 신규한 디히드로피라노피리미디논 유도체 및 이들의 용도 | |
JP2014530202A (ja) | コリンキナーゼ阻害剤として有用な化合物 | |
TW201629071A (zh) | 稠合雜環化合物 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
AMND | Amendment | ||
E902 | Notification of reason for refusal | ||
AMND | Amendment | ||
E601 | Decision to refuse application | ||
X091 | Application refused [patent] | ||
AMND | Amendment | ||
X701 | Decision to grant (after re-examination) | ||
GRNT | Written decision to grant |